Login to Your Account



Oncosec sings praise of booster bid for immunotherapy

By Randy Osborne
Staff Writer

Wednesday, November 26, 2014

The approval this fall of Merck & Co. Inc.'s lauded Keytruda for melanoma opened the door for the promising class of PD-1 inhibitors, and represented another stride in the steady march of immunotherapy in cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription